Skin Surface Lipid-RNA Profile Obtained from Patients with Severe Asthma After Benralizumab Treatment

Overview

Journal J Asthma Allergy

Publisher Dove Medical Press

Date 2024 Nov 11

PMID 39524483

Authors

Sonoko Harada

Hitoshi Sasano

Shoko Ueda

Yuuki Sandhu

Sumiko Abe

Yuki Tanabe

Kyoko Shima

Tetsuya Kuwano

Yuya Uehara

Takayoshi Inoue

Ko Okumura

Kazuhisa Takahashi

Norihiro Harada

Affiliations

Soon will be listed here.

Abstract

Background: Examining human coding and non-coding RNAs present in skin surface lipids (SSL-RNAs) offers a promising approach to understanding the physiological state of the skin. Benralizumab treatment can reduce exacerbations and improve symptom control and quality of life in patients with severe eosinophilic asthma. Although this treatment effectively depletes peripheral blood eosinophils, the impact of benralizumab on SSL-RNA remains completely unknown.

Objective: To investigate the effects of benralizumab treatment on SSL-RNA profiles in patients with severe asthma.

Methods: Skin samples were non-invasively collected from patients before and after one year of benralizumab treatment. Sixteen patients were enrolled, but the SSL-RNA analysis was only feasible for five patients due to collection challenges, mainly in female participants.

Results: Following benralizumab treatment, asthma symptoms, exacerbation rates, and lung function parameters improved. Peripheral blood eosinophils were completely depleted and serum eotaxin-1 levels increased. SSL-RNA analysis revealed differential expression of 134 genes, with significant downregulation of immune-related pathways and genes associated with neutrophilic inflammation.

Conclusion: These findings suggest a suppression of both type 2 and non-type 2 inflammation in response to benralizumab treatment, with potential implications for asthma management. However, the limitations of the study include a small sample size and challenges in sebum collection, particularly among female participants. Although the noninvasive nature of this sampling method makes it attractive for both research and clinical applications, additional studies are needed to fully investigate the potential of SSL-RNA analysis as a noninvasive biomarker to assess treatment response in asthma.

References

Papi A, Ryan D, Soriano J, Chrystyn H, Bjermer L, Rodriguez-Roisin R . Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma. J Allergy Clin Immunol Pract. 2018; 6(6):1989-1998.e3. DOI: 10.1016/j.jaip.2018.03.008. View

Gautier C, Charpin D . Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017; 10:47-56. PMC: 5349698. DOI: 10.2147/JAA.S121276. View

Berghi O, Vrinceanu D, Cergan R, Dumitru M, Costache A . allergy (A comprehensive review). Exp Ther Med. 2021; 22(4):1061. PMC: 8353643. DOI: 10.3892/etm.2021.10495. View

Sridhar S, Liu H, Pham T, Damera G, Newbold P . Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Respir Res. 2019; 20(1):14. PMC: 6339432. DOI: 10.1186/s12931-018-0968-8. View

Sandhu Y, Harada N, Sasano H, Harada S, Ueda S, Takeshige T . Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma. Biomolecules. 2023; 13(3). PMC: 10046637. DOI: 10.3390/biom13030538. View

Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C . Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respir Med. 2014; 108(12):1723-32. DOI: 10.1016/j.rmed.2014.10.007. View

Kallieri M, Zervas E, Fouka E, Porpodis K, Hadji Mitrova M, Tzortzaki E . RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response. Allergy. 2022; 77(9):2848-2852. DOI: 10.1111/all.15382. View

Paliwal S, Hwang B, Tsai K, Mitragotri S . Diagnostic opportunities based on skin biomarkers. Eur J Pharm Sci. 2012; 50(5):546-56. DOI: 10.1016/j.ejps.2012.10.009. View

Shima K, Inoue T, Uehara Y, Iwamura M, Fukagawa S, Kuwano T . Non-invasive transcriptomic analysis using mRNAs in skin surface lipids obtained from children with mild-to-moderate atopic dermatitis. J Eur Acad Dermatol Venereol. 2022; 36(9):1477-1485. PMC: 9545805. DOI: 10.1111/jdv.18173. View

10.

Abdo M, Watz H, Veith V, Kirsten A, Biller H, Pedersen F . Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study. Respir Res. 2020; 21(1):278. PMC: 7579879. DOI: 10.1186/s12931-020-01543-5. View

11.

Bousquet J, Chanez P, Lacoste J, Barneon G, Ghavanian N, ENANDER I . Eosinophilic inflammation in asthma. N Engl J Med. 1990; 323(15):1033-9. DOI: 10.1056/NEJM199010113231505. View

12.

Sehmi R, Lim H, Mukherjee M, Huang C, Radford K, Newbold P . Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma. J Allergy Clin Immunol. 2018; 141(4):1529-1532.e8. DOI: 10.1016/j.jaci.2018.01.008. View

13.

Hekking P, Loza M, Pavlidis S, De Meulder B, Lefaudeux D, Baribaud F . Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma. Eur Respir J. 2017; 50(3). DOI: 10.1183/13993003.02298-2016. View

14.

Mummler C, Munker D, Barnikel M, Veit T, Kayser M, Welte T . Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy. J Allergy Clin Immunol Pract. 2020; 9(3):1177-1185.e4. DOI: 10.1016/j.jaip.2020.09.014. View

15.

Ishimori A, Harada N, Chiba A, Harada S, Matsuno K, Makino F . Circulating activated innate lymphoid cells and mucosal-associated invariant T cells are associated with airflow limitation in patients with asthma. Allergol Int. 2016; 66(2):302-309. DOI: 10.1016/j.alit.2016.07.005. View

16.

Eger K, Kroes J, Ten Brinke A, Bel E . Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation. J Allergy Clin Immunol Pract. 2020; 9(3):1194-1200. DOI: 10.1016/j.jaip.2020.10.010. View

17.

Harada N, Ito J, Takahashi K . Clinical effects and immune modulation of biologics in asthma. Respir Investig. 2021; 59(4):389-396. DOI: 10.1016/j.resinv.2021.03.003. View

18.

Zhang X, Moilanen E, Kankaanranta H . Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur J Pharmacol. 2000; 406(3):325-32. DOI: 10.1016/s0014-2999(00)00690-7. View

19.

Nathan R, Sorkness C, Kosinski M, Schatz M, Li J, Marcus P . Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004; 113(1):59-65. DOI: 10.1016/j.jaci.2003.09.008. View

20.

Nair P, Wenzel S, Rabe K, Bourdin A, Lugogo N, Kuna P . Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017; 376(25):2448-2458. DOI: 10.1056/NEJMoa1703501. View